Gary A. Lyons, Director at Travere Therapeutics, Inc. (TVTX), sold 10,000 shares at $62.53 ($633K) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($633k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.53 | 1,900 | $119K | 18.8% |
| 2 | $63.50 | 2,600 | $165K | 26.1% |
| 3 | $64.16 | 500 | $32K | 5.1% |
| 4 | $63.27 | 4,100 | $259K | 41.0% |
| 5 | $63.86 | 900 | $57K | 9.1% |
| Total | $63.28 avg | 10,000 |
| $633K |
| 100% |
| Filing → |
| TVTX | SELL | 2024-10-04 | $1.2M | — | Filing → |
| NBIX | SELL | 2024-08-15 | $3.5M | — | Filing → |
| NBIX | SELL | 2024-07-18 | $279K | — | Filing → |